Preventing strokes from narrowed arteries inside the brain using blood thinners and antiplatelet medicines
Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis
['FUNDING_U01'] · UNIVERSITY OF FLORIDA · NIH-11177738
People with symptomatic narrowing of arteries inside the brain will receive different combinations of antiplatelet and anticoagulant medicines to compare which approach lowers their risk of repeat stroke.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF FLORIDA (nih funded) |
| Locations | 1 site (GAINESVILLE, UNITED STATES) |
| Trial ID | NIH-11177738 on ClinicalTrials.gov |
What this research studies
If you join, you will be randomly assigned to one of three medication plans that combine antiplatelet drugs or a novel oral anticoagulant with aspirin. The goal is to find which medication combination best prevents new strokes while balancing bleeding risk. Doctors will see you regularly for exams, imaging when needed, and blood tests to monitor side effects and outcomes over the follow-up period. The team will also collect genetic and other information (for example CYP2C19 results) to help understand who benefits most from each approach.
Who could benefit from this research
Good fit: Adults who recently had a stroke or TIA caused by symptomatic intracranial atherosclerotic narrowing (typically high-grade stenosis) are the main candidates for this trial.
Not a fit: People without intracranial atherosclerotic stenosis, or those at high risk for bleeding or with contraindications to antiplatelet/anticoagulant therapy, are unlikely to benefit or may be excluded.
Why it matters
Potential benefit: If successful, this could reduce the chance of repeat stroke and vascular death in people with symptomatic intracranial atherosclerotic narrowing.
How similar studies have performed: Previous trials like SAMMPRIS showed substantial residual stroke risk despite clopidogrel plus aspirin, ticagrelor offers stronger platelet inhibition but has not yet been proven to reduce strokes for this condition, and NOACs remain unproven in this specific setting.
Where this research is happening
GAINESVILLE, UNITED STATES
- UNIVERSITY OF FLORIDA — GAINESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HOH, BRIAN LIM — UNIVERSITY OF FLORIDA
- Study coordinator: HOH, BRIAN LIM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.